EUVIMEDEUVIMED entdecken
Crossref

“Ozempic Face” and the Dental Professional: Managing GLP-1 Receptor Agonist–Associated Facial Volume Loss Through Biostimulators and Minimally Invasive Orofacial Harmonization — A Narrative Review

Pedro César Mesquita Cals de Oliveira

IOSR Journal of Dental and Medical Sciences · 2026-10 · 25 (10) · 17-24

DOI: 10.9790/0853-2510051724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IOSR Journal of Dental and Medical Sciences, 2026-10. Verfasst von Pedro César Mesquita Cals de Oliveira.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and the dual agonist tirzepatide produce mean weight reductions of 15% to 21% in pivotal trials and have become one of the fastestgrowing drug classes in the United States. Rapid fat loss is accompanied by facial deflation, laxity and an aged appearance popularly called “Ozempic face”. Because the lower third of the face, the lips and the masticatory system are the daily territory of dentistry, dental professionals are often the first clinicians to observe these changes, yet the dental literature has barely addressed them. Materials and Methods: A narrative review was conducted in PubMed/MEDLINE (January 2014 to October 2026) using combinations of the terms semaglutide, tirzepatide, GLP-1, facial volume, aging, filler, biostimulator, poly-L-lactic acid, calcium hydroxylapatite, botulinum toxin, dentistry and oral health. Pivotal trials, imaging and survey studies, systematic and narrative reviews, consensus statements and state regulatory sources on dental scope of practice were synthesized qualitatively.

Results

Imaging data indicate a median midfacial volume loss of about 9%, roughly 7% per 10 kg lost, predominantly in superficial fat compartments; patient-reported facial volume loss rises from 13% with less than 10% weight loss to 50% with more than 20%. Current evidence attributes the phenotype to the speed and magnitude of weight loss superimposed on aging, rather than to a drug-specific toxicity. Contributing mechanisms include fat-compartment deflation, lean-mass loss, nutritional deficiency and skeletal aging. Oral consequences (xerostomia, dysgeusia, reflux-related erosion risk) and aspiration risk during sedation are also relevant to dental care. Treatment evidence is preliminary: a 2026 systematic review found only four uncontrolled studies with 98 participants. Biostimulators (poly-L-lactic acid and calcium hydroxylapatite) appear well suited to a tissuerebuilding rather than an “inflating” strategy, with hyaluronic acid used selectively for structural support.

Conclusion

Dentists trained in facial anatomy can contribute to the recognition, staged planning and conservative management of GLP-1–associated facial change, provided they work within state scope-of-practice rules, coordinate with prescribers, time interventions to weight stability and maintain complication protocols. A fivestep dental clinical pathway and a research agenda are proposed.

Zitieren

APA

Oliveira, P. C. M. C. D. (2026). “Ozempic Face” and the Dental Professional: Managing GLP-1 Receptor Agonist–Associated Facial Volume Loss Through Biostimulators and Minimally Invasive Orofacial Harmonization — A Narrative Review. IOSR Journal of Dental and Medical Sciences, 25(10), 17-24. https://doi.org/10.9790/0853-2510051724

Vancouver

Oliveira PCMCD. “Ozempic Face” and the Dental Professional: Managing GLP-1 Receptor Agonist–Associated Facial Volume Loss Through Biostimulators and Minimally Invasive Orofacial Harmonization — A Narrative Review. IOSR Journal of Dental and Medical Sciences. 2026;25(10):17-24. doi:10.9790/0853-2510051724

BibTeX
@article{Oliveira2026,
  author = {Oliveira, Pedro César Mesquita Cals de},
  title = {“Ozempic Face” and the Dental Professional: Managing GLP-1 Receptor Agonist–Associated Facial Volume Loss Through Biostimulators and Minimally Invasive Orofacial Harmonization — A Narrative Review},
  journal = {IOSR Journal of Dental and Medical Sciences},
  year = {2026},
  volume = {25},
  number = {10},
  pages = {17--24},
  doi = {10.9790/0853-2510051724}
}
Kostenlos starten →